Radiopharm Theranostics is developing a world-class platform of radiopharmaceutical and nuclear medicine products for both diagnostic and therapeutic uses.
External link for Radiopharm Theranostics
Sydney, AU
Radiopharm Theranostics reposted this
RAD is pleased to announce it has received clearance for its Investigational New Drug (IND) application with the US #FDA, for F18-Pivalate (RAD 101): https://buff.ly/3SiRH3e The IND approval is a clear recognition by the FDA of clinical data already generated for RAD 101 and is a significant milestone towards starting a Phase 2b multi-center trial for the imaging of brain metastases. #biotech #medtech
RAD is pleased to announce it has received clearance for its Investigational New Drug (IND) application with the US #FDA, for F18-Pivalate (RAD 101): https://buff.ly/3SiRH3e The IND approval is a clear recognition by the FDA of clinical data already generated for RAD 101 and is a significant milestone towards starting a Phase 2b multi-center trial for the imaging of brain metastases. #biotech #medtech
RAD is pleased to be presenting at 12:30PM AEST in today's ShareCafe Hidden Gems webinar. Register for free at: https://lnkd.in/emiABZRa
Friday's webinar will discuss battery minerals, radiopharmaceutical products and cancer treatments. Register now https://bit.ly/4cXvNKO to hear from QX Resources ASX: QXR, Radiopharm Theranostics ASX: RAD & Arovella Therapeutics ASX: ALA
RAD was featured in the latest edition of Rat's Rant by Nick Kelso, where he discussed our recent $70m placement and cornerstone investment from Lantheus, as well as our current clinical pipeline: https://buff.ly/3Y4f5FA #biotech #medtech #radiopharma #ASX
The first patient has been dosed with RAD 204 (PD-L1 nanobody) in a Phase 1 therapeutic trial at Wollongong Hospital: https://buff.ly/4eYJ1IW 16 patients previously dosed in Phase 1 diagnostic study demonstrated safety and effective biodistribution, and validate the strong potential for ¹⁷⁷Lu-RAD204 for the treatment of advanced NSCLC. #biotech
Missed yesterday's investor webinar? A replay is now available at: https://buff.ly/45X1fXl CEO & MD Riccardo Canevari and Executive Chairman Paul Hopper provided an update following announcement of our $70m capital raising.
Prominent small-cap share analyst and business journalist tim boreham has written a feature on RAD which was published in last Friday's edition of Biotech Daily, where he discussed the recent $70 million capital raise as well as the Company's clinical programs. Click here to view the feature: https://buff.ly/3VJGppL
CEO & MD Riccardo Canevari and Executive Chairman Paul Hopper will conduct an investor webinar to provide an update following announcement of our $70m capital raising. When: 3pm AEST, Tuesday 2 July 2024 Register: https://buff.ly/4brVLF4
"This [Lantheus] partnership not only boosts RAD’s financial footing but also strategically aligns it with a seasoned entity in the radiopharmaceutical field, potentially accelerating its pipeline development & enhancing its market presence." Latest report from Diamond Equity Research on $RAD, setting a A$0.50 price target: https://buff.ly/3XNw5iW
RAD Chairman Paul Hopper joined ausbiz today to discuss our recently announced ~$70m capital raise supported by institutional & industry investors, including Lantheus: https://buff.ly/4eGXh9a He also provided an update on the progress of our current clinical programs. #medtech #biotech